Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523700 | 1.00 | L3MBTL1 (0.48) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL28891113 | 0.88 | FFAR1 (0.57) | L3MBTL1KDM1ALMNAMAOB | |
| SCHEMBL6216693 | 0.87 | HTR1A (0.51) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL11840264 | 0.85 | L3MBTL1 (0.49) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL2394733 | 0.84 | L3MBTL1 (0.48) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL27090052 | 0.84 | L3MBTL1 (0.51) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL2394736 | 0.84 | L3MBTL1 (0.48) | L3MBTL1KDM1ALMNAHTR1ADRD2 | |
| SCHEMBL2568609 | 0.83 | HTR1A (0.67) | L3MBTL1LMNAHTR1ADRD2MAOB | |
| SCHEMBL31166868 | 0.82 | MAOB (0.57) | L3MBTL1LMNAMAOBMAPTLTA4H | |
| Hydrochloric Acid SCHEMBL6482842 | 0.81 | HTR1A (0.65) | L3MBTL1LMNAHTR1ADRD2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2675803-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | Elanco Animal Health Ireland Limited (IE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2488521-B1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND (IE) | 2013-12-18 | — | — | EP | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-8497270-B2 | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2012112345-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2488521-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Elanco Animal Health Ireland Limited (IE) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011045330-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | FIP1L1, PIM1, TYMP | L3MBTL1 2476/4885KDM1A 1142/4885LMNA 2097/4885 |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | CCNI, CCNY, CDK7 | L3MBTL1 478/4885KDM1A 498/4885LMNA 1755/4885 |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | L3MBTL1 2613/4885KDM1A 4626/4885LMNA 1628/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | L3MBTL1 2613/4885KDM1A 4626/4885LMNA 1628/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | L3MBTL1 2613/4885KDM1A 4626/4885LMNA 1628/4885 |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | L3MBTL1 2444/4885KDM1A 4633/4885LMNA 1469/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | L3MBTL1 2613/4885KDM1A 4626/4885LMNA 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.